Fig. 5: Cotadutide increases brown adipose tissue glucose uptake.

Analysis of glucose uptake in DIO mice following 28-day treatment of cotadutide (10 nmol/kg, blue upward triangles), liraglutide (5 nmol/kg, purple downward triangles) (A, B), 10 nmol/kg (C–E)), or g1437 (5 nmol/kg, gold diamonds), compared to vehicle (red circles). Tissue-specific glucose uptake (Rd) in gastrocnemius (Gastroc), vastus lateralis (Vastus L), perigonadal adipose tissue (PG AT), subcutaneous adipose tissue (SubQ AT) (A), soleus muscle, brown adipose tissue (Brown AT), heart, and brain tissue (B). Vechicle (n = 9), cotadutide (n = 8), liraglutide (n = 9), g1437 (n = 8). Reduction in body weight (BW) throughout the 28-day dosing period is shown as % change, with fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging timepoints indicated (C). n = 8 mice per group. Quantification of FDG-PET glucose uptake measurements in brown adipose tissue (BAT) at baseline, day 14, or day 28 of treatment (D). Representative image from FDG-PET studies summarized in (D), (E). n = 8 mice per group, except cotadutide baseline (n = 4), liraglutide D14 (n = 7), g1437 D14 (n = 7). Data shown as the mean ± SEM. In (C), lines below the graph indicate differences compared with a vehicle at each time point and correspond to the respective group color. One-way ANOVA with Tukey’s multiple comparisons post hoc for each tissue (A, B) or each treatment group (D), Two-way ANOVA with Tukey’s multiple comparisons post hoc (C). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < .0001. Exact p values are included in the Source Data file. Source data are provided as a Source Data file.